This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
bacteria:t3e:xopac [2020/07/03 09:12] – rkoebnik | bacteria:t3e:xopac [2025/02/12 23:11] (current) – jfpothier | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== XopAC ====== | + | ====== |
Author: [[https:// | Author: [[https:// | ||
- | Internal reviewer: | + | Internal reviewer: |
- | Expert reviewer: | + | Expert reviewer: |
Class: XopAC\\ | Class: XopAC\\ | ||
Family: XopAC\\ | Family: XopAC\\ | ||
- | Prototype: XopAC (// | + | Prototype: XopAC (// |
- | RefSeq | + | GenBank |
- | 3D structure: | + | RefSeq ID: [[https:// |
+ | 3D structure: | ||
===== Biological function ===== | ===== Biological function ===== | ||
Line 15: | Line 16: | ||
=== How discovered? === | === How discovered? === | ||
- | XopAC/AvrAC was identified as a putative type III effector because of the presence of seven prokaryotic-type leucine-rich repeats in its C-terminal domain and a PIP-box motif in //xopAC// promoter suggestive of a // | + | XopAC/AvrAC was identified as a putative type III effector because of the presence of seven prokaryotic-type leucine-rich repeats in its C-terminal domain and a PIP-box motif in the //xopAC// promoter suggestive of a // |
=== (Experimental) evidence for being a T3E === | === (Experimental) evidence for being a T3E === | ||
- | The first XopAC< | + | The N-terminal region of XopAC (XopAC< |
=== Regulation === | === Regulation === | ||
- | //xopAC// promoters possess a PIP-box motif (Xu //et al//., 2008). Expression of //xopAC// is induced in // | + | //xopAC// promoters possess a PIP-box motif (Xu //et al//., 2008). Expression of //xopAC// is induced in the // |
=== Phenotypes === | === Phenotypes === | ||
- | //xopAC//, also named //avrAC//, confers avirulence to // | + | * //xopAC//, also named //avrAC//, confers avirulence to // |
+ | * //xopAC// avirulence is weak in mesophyll tissue but strong upon inoculation of hydathodes or vascular tissues (Xu //et al//., 2008; Cerutti //et al//., 2017). | ||
+ | * //xopAC// contributes to //Xcc// pathogenicity on //Brassica oleracea// and //Arabidopsis// in a // | ||
+ | * XopAC inhibits BIK1 kinase activity and blocks flg22-induced PTI responses (Feng //et al//., 2012). | ||
+ | * XopAC was found to be associated with variations in disease symptoms when testing a set of 45 //Xcc// strains on two natural accessions of // | ||
+ | * Mutagenesis of type III effectors in //Xcc// confirmed that //xopAC// functions as both a virulence and an avirulence gene in // | ||
+ | * When heterologously expressed in virulent //Ralstonia solanacearum// | ||
+ | * Transgenic expression of //xopAC// in //Arabidopsis// accession Col-0 induces early growth arrest at both apical and root meristems (Wang //et al//., 2015). | ||
+ | * AvrAC recognition requires the RKS1 pseudokinase of the ZRK family and the NLR protein ZAR1, which also recognizes the // | ||
=== Localization === | === Localization === | ||
- | XopAC was localized to the plasma membrane upon // | + | XopAC was localized to the plant plasma membrane upon // |
=== Enzymatic function === | === Enzymatic function === | ||
- | XopAC presents an uridylyl transferase activity | + | XopAC presents an uridylyl transferase activity, which depends |
=== Interaction partners === | === Interaction partners === | ||
- | Nine // | + | Nine // |
===== Conservation ===== | ===== Conservation ===== | ||
=== In xanthomonads === | === In xanthomonads === | ||
- | xopAC is present in many //Xanthomonas campestris// | + | xopAC is present in many //Xcc// strains as well as several // |
=== In other plant pathogens/ | === In other plant pathogens/ | ||
- | No. | + | Yes, //Ralstonia solanacearum// |
===== References ===== | ===== References ===== | ||
Line 49: | Line 63: | ||
Feng F, Yang F, Rong W, Wu X, Zhang J, Chen S, He C, Zhou JM (2012). A // | Feng F, Yang F, Rong W, Wu X, Zhang J, Chen S, He C, Zhou JM (2012). A // | ||
- | Guy E, Genissel A, Hajri A, Chabannes M, David P, Carrère S, Lautier M, Roux B, Boureau T, Arlat M, Poussier S, Noël LD (2013a). Natural genetic variation of // | + | Guy E, Genissel A, Hajri A, Chabannes M, David P, Carrère S, Lautier M, Roux B, Boureau T, Arlat M, Poussier S, Noël LD (2013a). Natural genetic variation of // |
Guy E, Lautier M, Chabannes M, Roux B, Lauber E, Arlat M, Noël LD (2013b). // | Guy E, Lautier M, Chabannes M, Roux B, Lauber E, Arlat M, Noël LD (2013b). // | ||
+ | |||
+ | Laflamme B, Dillon MM, Martel A, Almeida RND, Desveaux D, Guttman DS (2020). The pan-genome effector-triggered immunity ladscape of a host-pathogen interaction. Science 367: 763-768. DOI: [[http:// | ||
+ | |||
+ | Schultink A, Qi T, Bally J, Staskawicz B (2019). Using forward genetics in //Nicotiana benthamiana// | ||
+ | |||
+ | Tan X, Qiu H, Li F, Cheng D, Zheng X, Wang B, Huang M, Li W, Li Y, Sang K, Song B, Du J, Chen H, Xie C (2019). Complete genome sequence of sequevar 14M //Ralstonia solanacearum// | ||
Wang G, Roux B, Feng F, Guy E, Li L, Li N, Zhang X, Lautier M, Jardinaud MF, Chabannes M, Arlat M, Chen S, He C, Noël LD, J.M. Zhou JM (2015). The decoy substrate of a pathogen effector and a pseudokinase specify pathogen-induced modified-self recognition and immunity in plants. Cell Host Microbe 18: 285-295. DOI: [[https:// | Wang G, Roux B, Feng F, Guy E, Li L, Li N, Zhang X, Lautier M, Jardinaud MF, Chabannes M, Arlat M, Chen S, He C, Noël LD, J.M. Zhou JM (2015). The decoy substrate of a pathogen effector and a pseudokinase specify pathogen-induced modified-self recognition and immunity in plants. Cell Host Microbe 18: 285-295. DOI: [[https:// | ||
- | Xu RQ, Blanvillain S, Feng JX, Jiang BL, Li XZ, Wei HY, Kroj T, Lauber E, Roby D, Chen B, He YQ, Lu GT, Tang DJ, Vasse J, Arlat M, Tang JL (2008). AvrAC< | + | Xu RQ, Blanvillain S, Feng JX, Jiang BL, Li XZ, Wei HY, Kroj T, Lauber E, Roby D, Chen B, He YQ, Lu GT, Tang DJ, Vasse J, Arlat M, Tang JL (2008). AvrAC< |
+ | |||
+ | ===== Acknowledgements ===== | ||
+ | |||
+ | This fact sheet is based upon work from COST Action CA16107 EuroXanth, supported by COST (European Cooperation in Science and Technology). | ||